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Summary
a-Mannosidosis is an autosomal recessive lysosomal-
storage disorder caused by a deficiency of lysosomal a-
mannosidase activity. This disease shows a wide range
of clinical phenotypes, from a severe, infantile form (type
I), which is fatal at !3–8 years of age, to a less severe,
late-onset form (type II), which ultimately may involve
hearing loss, coarse face, mental retardation, and he-
patosplenomegaly. To elucidate the molecular mecha-
nism underlying this disease in both types of patients,
we have used PCR, followed by either SSCP analysis or
direct sequencing, to analyze the 24 exons and intron/
exon boundaries of the a-mannosidase gene (MANB)
from five patients. Two amino acid substitutions—H72L
and R750W, in exons 2 and 18, respectively—and two
nonsense mutations—Q639X and R760X, in exons 15
and 19, respectively—were identified in four type II pa-
tients. One amino acid substitution, P356R, was iden-
tified in exon 8 from a type I patient. This patient and
three of the type II patients were homozygous for their
mutations (H72L, P356R, R750W, and R760X) and one
type II patient was heterozygous for the Q639X and
R750W mutations. Transfection experiments of COS 7
cells, using the a-mannosidase cDNA containing
one of the missense mutations—H72L, P356R, or
R750W—revealed that each of these mutations dra-
matically reduces the enzymatic activity of a-mannosi-
dase. These data demonstrate that widely heterogeneous
missense or nonsense mutations of the MANB gene are
the molecular basis underlying a-mannosidosis.
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Introduction
Lysosomal a-mannosidase (E.C.3.2.1.24) is a lysosomal
hydrolase that cleaves a-linked mannose residues from
the nonreducing end of N-linked glycoproteins. Human
lysosomal a-mannosidase has been purified from various
tissues, and two polypeptides have been identified to be
either ∼60 and 30 kD (Cheng et al. 1986; Emiliani et
al. 1995) or 65 and 27 kD (Tsuji and Suzuki 1987).
Recently, a single cDNA clone of this enzyme was iso-
lated from retina/muscle cDNA libraries (Nebes and
Schmidt 1994) and from spleen, fibroblast, and lung
cDNA sources (Liao et al. 1996; Nilssen et al. 1997).
Transfection experiments using this cDNA gave in-
creased lysosomal a-mannosidase enzyme activity inmu-
rine fibroblasts (Wang et al. 1996) and in Pichia pastoris
(Liao et al. 1996), confirming that the cloned cDNAs
encode human lysosomal a-mannosidase. From the
amino acid sequence of the protein purified from pla-
centa, a single-chain precursor protein of lysosomal a-
mannosidase was shown to be processed into three pep-
tides, which have molecular weights of 70, 42, and 13
or 15 kD (Nilssen et al. 1997).
Deficiency of a-mannosidase results in the autosomal
recessive lysosomal-storage disorder, a-mannosidosis
(MIM 248500). a-Mannosidosis shows a wide range of
clinical phenotypes, from a severe infantile phenotype
(type I), which shows rapid mental deterioration, hy-
potonia, hepatosplenomegaly, severe dysostosis multi-
plex, and, often, death at !3–8 years of age, to a milder
phenotype (type II), which is characterized by normal
early development, mental retardation during child-
hood, and survival well into adulthood (Thomas and
Beaudet 1995).
Using the a-mannosidase cDNA clone (Nebes and
Schmidt 1994) as a probe, we isolated and analyzed
genomic clones of the human MANB gene (Wakamatsu
et al. 1997). Riise et al. (1997) have determined the
genomic structure of the MANB gene by using a PCR-
based strategy. This gene spans ∼22 kb and consists of
24 exons. The 5′-flanking region of the gene shows a
high GC content and has two Sp1 sites and three AP-
2 sites. The availability of a genomic clone made it pos-
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Table 1
Clinical and Biochemical Findings in Patient with a-Mannosidosis
Patient (Cell Line)






1 (OK1) [F; 47 years] Japanese Mental retardation, hearing loss, coarse facial features !1 Leukocytes
2 (GM654) [M; 7 years] Finnish Mental retardation, hearing loss, coarse facial features 2 Fibroblasts
3 (GM2051) [F; 7 years] Arabian Unknown !1 Fibroblasts
4 (GM2817) [F; 6 years] Unknown Unknown 2 Fibroblasts
5 (GM4518) [F; 2 years] Unknown Severe growth failure, hypotonia, psychomotor retar-
dation, hepatosplenomegaly
!1 Fibroblasts
a For leukocytes, mean ( standard error of the mean) control activity was 2.98 (0.29) nmol/min/mg protein ( ); for fibroblasts, meann  5
( standard error of the mean) control activity was 1.43 (0.09) nmol/min/mg protein ( ).n  5
sible to investigate the molecular defects associated with
a-mannosidosis, with hopes of determining the molec-
ular basis underlying both types of phenotypic variants.
In this effort, we prepared specific oligonucleotides to
amplify all 24 exons and flanking sequences, for use in
a mutation analysis of the gene in five patients. We iden-
tified several mutations from five patients with a-man-
nosidosis, revealing not only that the disease is caused
by mutation of theMANB gene but that a heterogeneous
collection of nonsense and missense mutations provide
the molecular basis underlying a-mannosidosis.
Subjects and Methods
Subjects
Patient 1 (OK1).—Patient 1 is a 47-year-old Japanese
female born to a consanguineous marriage in which the
parents were first cousins. She has suffered from recur-
ring infections, such as bronchitis and otitis media, since
her 1st year of life. Hearing disturbance and delayed
psychomotor development were noticed at age 2 years,
by her parents. When she was 9 years old, she entered
a school for the deaf, where she did poorly. She gradually
developed a gait disturbance and was admitted to our
hospital at age of 36 years. A physical examination re-
vealed mental retardation, with an IQ of 19; coarse face;
retinal degeneration; sensorineural hearing loss; in-
creased deep-tendon reflexes; spastic gait; and mild limb
ataxia. There were vacuolated lymphocytes in her pe-
ripheral blood. Similar vacuoles were also present in her
biopsied muscle cells and fibroblasts. The lysosomal a-
mannosidase activity of the peripheral leukocytes was
markedly decreased, to !1% of that in normal control
subjects, whereas other lysosomal enzyme activi-
ties—such as a-galactosidase, b-galactosidase, and b-
hexosaminidase—were all within the normal range.
Thin-layer chromatography of the patient’s urine
showed an enhanced excretion of oligosaccharides.
From these clinical and laboratory findings, she was di-
agnosed as having a-mannosidosis (table 1). Her
younger sister (OK2) was age 42 years and had clinical
history and features that were similar to those of patient
1; the results of the pathological examination of muscle
from this sister have been reported elsewhere (Kawai et
al. 1985).
Patient 2 (cell line GM654).—The clinical character-
istics of patient 2 have been described elsewhere (Autio
et al. 1973; also see table 1). In brief, the patient is the
only child of healthy nonconsanguineous parents. The
parents did not notice anything abnormal during this
child’s 1st year of life, except for recurring infections.
By age 17 mo, he was speaking only a few words, and
impaired hearing was suspected. He was noticed to have
coarse facial features, delayed psychomotor functions,
and brisk tendon reflexes when examined at age 17 mo
in the Children’s Hospital. Approximately 80% of his
peripheral blood leukocytes were vacuolized, and his a-
mannosidase activity was decreased to only a few per-
cent of that in normal control subjects. He often suffered
from respiratory infections but was living well at home.
Patient 3 (cell line GM2051), patient 4 (cell line
GM2817) and patient 5 (cell line GM4518).—The skin
biopsies of patients 3, 4, and 5 were done at ages 7, 6,
and 2 years, respectively. The clinical characteristics of
these patients were not available, except for those of
patient 5, who showed severe growth failure, with hy-
potonia, psychomotor retardation, and hepatosplen-
omegaly (table 1).
The cultured skin-fibroblast cell lines GM654,
GM2051, GM2817, and GM4518 were obtained from
the Human Genetic Mutant Cell Repository (Camden,
NJ). These cell lines weremaintained ina-MEMmedium
supplemented with 20% FCS at 37C.
Enzyme Activity
Leukocytes and cultured fibroblasts were homoge-
nized with 20 mM sodium phosphate buffer, pH 6.0,
containing 0.5 % Triton X-100. The supernatants were
assayed for a-mannosidase activity and protein concen-
tration (Bradford 1976). Lysosomal a-mannosidase ac-
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manE1S/A 1 ACCCCAGGAGGAAGCTGCTGA TCACTCTGCCTCCTGTACGT 58
manE2S/A 2 GGGGGTTATTGACAAGGTAT TGGGGATCCCAGGGACCAGT 56
manE3S/A 3 CTGCTGTTCCCTGAGAGCCT CTGGGCTTCCTCTTTTCACT 60
manE4S/A 4 CTCTGACCGCTGACCCTGAC GTGAAGAAGTGGGCCCAAGA 58
manE5S/A 5 GGTGAGAGGGCTGGGCACTAAT GTGGCACCATGGCTGGCCCTGC 67
manE6S/A 6 GGTGATGGGCCACCCCTTGA CATTGTATTGTATATACCGGACT 58
manE7S/A 7 GGATCCTCTGGCTTCAGGACT CGGATGCAAGCGCACATGTGCA 57
manE8S/A 8 GCGGACTCCCGAGGGCTCACT GGTCATGACCCACGGGGCATG 62
manE9S/A 9 TTGGCATGCCCCGTGGGTCAT GTCGGGCCTCGGGGCTGCATG 67
manE10S/A 10 AGCCCCGAGGCCCGACAGGCT TCCAACTTCAGCCTCAAACCT 62
manE11S/A 11 TGAGTCCCACAGAACCTCACT CCTGTCTCCACCCCCGTGTCT 62
manE12S/A 12 CGTCCTGAACCCACCGGTCC GCCCATCTGCCCTAGATCCA 58
manE13S/A 13 TGTGACCCATGCCCTCTCTG GGAGTCCCAGCGGGGGAATA 58
manE14S/A 14 GGTACTCTTGACTCAGTTTC ACAGGAGCAGGAAAGGGGAT 58
manE15S/A 15 TAACACACAACCCATCTGT GCCCTAGCTCCATGCCGAGC 58
manE16S/A 16 CTAGGGCCCCTTACCTGACT CATTCCCAACTGCCCACTC 62
manE17S/A 17 GCTCAGGTACAGACTGACAT CCTCTGCCCTTGCTTCCACA 58
manE18S/A 18 AGAGGGGTTTATCCAAGGCT CCACAGACCACCCCCTCAGT 58
manE19S/A 19 GGAGCCAGATCCCAAGCCTG GGTGATTCCCTTTCTATCGA 58
manE20S/A 20 TGGGGTTGACTGCCCTCTAC TGGGAGGACCCTGGCTCGGA 58
manE21S/nA 21 CAAGGACACCCACAAACCCACG CCGGTGTCCGGCGGCTGCAG 62
manE21nS/A 21 TGGTGCTGCTGGACACAGCCCAG AAACCCGGCTCCCTGGTAGACT 67
manE22S/A 22 CCGCCCCTCTCCAACTCAGC TCTCTCCGATCTCCTTCTCA 58
manE23S/A 23 GCTTTGCCCCAACTCATCTG TGCCGGCCCCAGGTAAGACT 58
manE24S/A 24 CACCTCCTCACTCCTCCTTC ACACTCAGTCACAGAGCGAC 58
Restriction enzyme:
manE2MuS/A 2 AACGTGCACCTGCTGCCTCACAAGC TGGGGATCCCAGGGACCAGT 50
manE8S/A 8 GCGGACTCCCGAGGGCTCACT GGTCATGACCCACGGGGCATG 62
manE15MuS/16A 15 AGCAACTCCTGCTGCCTGTTCTC CATTCCCAACTGCCCACTC 62
manE18S/A 18 AGAGGGGTTTATCCAAGGCT CCACAGACCACCCCCTCAGT 58
manE19MuS/A 19 TCACCCCCAACCCCAGGCGGGAATAT GGTGATTCCCTTTCTATCGA 57
Mutagenesis:
man72LS/A 1–5 GAAGCTGCTGAGCCATGGGCGCCTAC AAGCCCATCTCGCGAAACAGCG 65
man750WS/A 16–21 CCAGTATAGGTGACAACGAAAGTGAC TGCGCGGAGGAGCCCCGAGATTGTA 57
T3/man356RA1 1–8 AATTAACCCTCACTAAGGGG GTAACAAGCGCGGGTGGAGTAGa 50
man356RS/A2 8–10 CTACTCCACCCGCGCTTGTTACa TGCACACCTGCAGGAAGTTGTA 50
a The mutation site is underlined.
tivity was determined by use of 2 mM 4-methylumbel-
liferyl (MU) a-mannopyranoside (Sigma) as substrate.
The enzyme assay was terminated by the addition of 2
ml of 0.2 M glycine NaOH buffer, pH 10.6. One unit
of enzyme activity was defined as the hydrolysis of 1
nmol of substrate for 1 min at 37C. Product formation
was determined by the increase in fluorescence, mea-
sured by a F3010 Fluorescence Spectrophotometer (Hi-
tachi) with excitation wavelength at 365 nm and emis-
sion wavelength at 448 nm.
PCR Amplification, Screening by SSCP, and DNA
Sequencing
Genomic DNA was isolated from peripheral blood or
cultured skin fibroblasts, according to standard proto-
cols. The primer pairs used for the amplification of each
exon, exon/intron boundary, and part of the associated
introns were determined according to the intron se-
quence near each splice junction (table 2). Fifty nano-
grams of genomic DNA from each patient and normal
control subject was amplified by PCR in a total volume
of 20 ml containing 0.2 mg of each primer, 20 mM of
each dNTP, 1.5 mM MgCl2, 20 mM Tris-HCl (pH8.4),
50 mM KCl, 1 unit of Taq DNA polymerase (Takara
Shuzo), and 0.5 ml of a-[32P]dCTP (5 mCi; 3,000 Ci/
mmol). PCR samples were preheated at 94C for 5 min.
Thirty PCR cycles were performed; each cycle consisted
of 40 s denaturation at 94C, 40 s at optimal annealing
temperature (table 2), and 1 min extension at 72C. For
SSCP analysis, PCR products were denatured by boiling,
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Figure 1 Partial nucleotide sequences of amplified MANB genomic DNA, confirming single-base substitutions in exons 2 (A), 8 (B), 15
(C), 18 (D), and 19 (E). Arrows indicate the positions of the nucleotide substitutions.
immediate cooling on ice, and separation on 6 % non-
denaturing polyacrylamide gels containing 10% glyc-
erol, 1 # Tris borate EDTA, for 12 h at room temper-
ature. The gels were dried and exposed to X-ray film
(X-OMAT; Kodak).
Identification of Mutations
On SSCP analysis, patients’ samples that, compared
with those from normal control subjects, exhibited either
band shifts or additional bands were used for direct se-
quencing. Genomic DNA from patients and normal con-
trol subjects were amplified by PCR, with the same
primer pairs that were used in the SSCP analysis. The
resultant PCR products were isolated from 8% poly-
acrylamide gels, were purified, and were directly se-
quenced by Sequenase (UBS), with a-[35S]dATP used as
tracer (Winship 1989). In the case of patient 1 (OK1),
the SSCP pattern failed to reveal band shifts for any of
the PCR products, so direct sequencing of all exons and
flanking sequences was performed.
To identify the mutations, PCR-dependent restriction-
enzyme diagnostic tests were established for each case.
Fifty nanograms of genomic DNA was used in each of
the following PCR amplifications. Genomic DNA con-
taining exon 2 and part of intron 2 of the MANB gene
from either patient 3 or normal control subjects was
amplified by specific primers (sense, manE2MuS; and
antisense, manE2A; see table 2), to detect creation of a
HindIII site in the mutant DNA. Genomic DNA con-
taining intron 15, exon 16, and part of exon 15, and
part of intron 16 of the MANB gene from patient 2 and
form normal control subjects was amplified by specific
primers (sense, manE15MuS; and antisense, manE15A;
table 2) to detect creation of an XbaI site in the mutant
DNA. Genomic DNA containing exon 19, part of intron
18, and part of intron 19 of the MANB gene from pa-
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Table 3
Mutations Identified in the MANB Gene
Patient
(Cell Line) Codon Nucleotide Change Coding Effect Consequence
Homozygosity
Statusa Region
1 (OK1) 760 CGArTGA Nonsense R760X  Exon 19
2 (GM654) 639 CAGrTAG Nonsense Q639X – Exon 15
750 CGGrTGG Missense R750W – Exon 18
3 (GM2051) 72 CATrCTT Missense H72L  Exon 2
4 (GM2817) 750 CGGrTGG Missense R750W  Exon 18
5 (GM4518) 356 CCCrCGC Missense P356R  Exon 8
a A plus sign () denotes presence of homozygosity, and a minus sign () denotes absence of homozygosity.
tient 1 and normal control subjects was amplified by
specific primers (sense, manE19MuS; and antisense,
manE19A; table 2) to detect creation of an SspI site in
the mutant DNA. The remaining mutations, including
both the shared mutation in patients 2 and 4 and the
mutation in patient 5, abolish an MspI site and created
a HhaI site, in exon 18 and exon 8, respectively. These
were evaluated, in patient and control samples, by PCR
of genomic DNA by specific primers (table 2). Ampli-
fication was performed for 30 cycles; each cycle con-
sisted of denaturation for 40 s at 94C, annealing for
40 s at optimal annealing temperature (table 2), and
extension for 1 min at 72C. The PCR products were
digested with HindIII, XbaI, SspI, MspI, or HhaI, were
electrophoresed on 8% polyacrylamide gels, and were
stained with ethidium bromide.
Preparation of Expression Vectors for Normal and
Mutant Human Lysosomal a-Mannosidase
For each of the constructs, first-strand cDNAwas syn-
thesized, by reverse transcription of 10 mg of total RNA
from the patient’s fibroblasts (cell lines GM2051 and
GM2817), by 200 units of Moloney murine leukemia
virus reverse transcriptase (Gibco-BRL) and 0.2 mg of
specific antisense primers, for 50 min at 42C (table 2).
1. Construction of the a-mannosidase expression vec-
tor, pCMV-Man.—The 3.1-kb NotI fragment of full-
length human MANB cDNA in plasmid SK() ( Nebes
and Schmidt 1994) was subcloned into the NotI site of
pCMV, an expression vector driven by the human cy-
tomegalovirus promoter/enhancer (pCMV-Man).
2. Introduction of exon 2 mutation (H72L).—The 3.1-
kbNotI fragment of the MANB cDNAwas inserted into
the NotI site of plasmid KS() (KS-Man). A part of the
MANB cDNA extending from exon 1 to part of exon
5 was amplified from cell line GM2051, by PCR (table
2). The amplification was performed for 30 cycles; each
cycle consisted of 1 min denaturation at 94C, 1 min
annealing at 65C, and 2 min extension at 72C. The
PCR product was digested with XhoI and StuI and was
inserted into the XhoI/StuI site of cleaved KS-Man (KS-
Man72L). Finally, the 3.1-kb NotI fragment of pCMV-
Man was replaced by the 3.1-kb NotI fragment of KS-
Man72L (pCMV-Man72L).
3. Introduction of exon 18 mutation (R750W).—Apor-
tion of the MANB cDNA extending from part of exon
16 to part of exon 21 was amplified from cell line
GM2817 by PCR (table 2). Amplification was per-
formed for 30 cycles; each cycle consisted of 1 min de-
naturation at 94C, 1 min annealing at 57C, and 2 min
extension at 72C. The PCR product was digested with
Eco81I and was inserted into theEco81I-cleavedpCMV-
Man (pCMV-Man750W).
4. Introduction of exon 8 mutation (P356R).—Two
parts of the MANB cDNA, extending from exon 1 to
part of exon 8 and from exon 8 to part of exon 10,
were amplified by specific primers (T3/man356RA1 and
man356RS/A2 respectively; see table 2) from plasmid
KS-Man, by Pfu DNA polymerase (Stratagene). In each
PCR incubation, one primer has the codon 356
(CCCrCGC) mutation (see table 2, where the mutation
site is underlined). Amplification was performed for 20
cycles; each cycle consisted of 1 min denaturation at
94C, 1 min annealing at 50C, and 3 min extension at
72C. The PCR products were electrophoresed on a 1.5
% agarose gel, were isolated, and were purified with
QIAEX II (QIAGEN). The purified PCR products were
mixed and amplified by Pfu DNA polymerase, with T3/
man356RA2 primers. Amplification was performed for
20 cycles, under the same conditions. The PCR product
was digested with NaeI and NotI and was inserted into
the NaeI/NotI site of cleaved 5.7-kb pCMV-Man
(pCMV-Man356R). The structures of these expression vec-
tors were confirmed by restriction mapping, as well as
by nucleotide-sequence analysis.
Cell Culture, DNA Transfection, and a-Mannosidase
Activity
COS 7 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inacti-
vated FCS. The cells were transfected with 10 mg of test
plasmid and 0.5 mg of the pCMVb control plasmid,
which is an expression vector containing the Escherichia
coli b-galactosidase gene. Transfection was accom-
Figure 2 Confirmation of mutations, by PCR-dependent restriction-enzyme diagnosis. Genomic DNA from the patients and from two unrelated normal individuals was amplified by specific
primers (table 2). The schematics below each panel show both the position of the restriction-enzyme site and the size of the fragments produced after restriction-enzyme digestion of the PCR product
from normal control DNA and from the mutant DNA. At the top of each panel the migration of the restricted fragments can be seen in an 8% polyacrylamide gel stained with ethidium bromide.
A, Patient 3. B, Patient 5. C, Patient 2. D, Patients 2 and 4. E, Patient 1.
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Figure 3 a-Mannosidase activities in COS 7 cells transfected
with a-mannosidase cDNAs. COS 7 cells were cotransfected with 0.5
mg of pCMVb control plasmid and 10 mg of test plasmid containing
either normal mannosidase cDNA (pCMV-Man) or mutant cDNA
(pCMV-Man72L, pCMV-Man356R, and pCMV-Man750W), or they were
mock transfected (i.e., were transfected without test plasmid [Mock]).
a-Mannosidase activity was measured, with 4-MU a-D-mannopyra-
noside used as a substrate. The columns indicate the mean of a-man-
nosidase (blackened cols.) and E. coli b-galactosidase (unblackened
cols.) activities, and vertical bars indicate standard error of the mean
( ).n  3
plished by the calcium phosphate coprecipitation
method (Wigler et al. 1978). Ten hours later, the medium
was replaced with the fresh medium, and, after an ad-
ditional 48-h culture, the COS 7 cells were harvested
and homogenized with 20mM sodium phosphate buffer,
pH 6.0, containing 0.5 % Triton X-100. The superna-
tants were assayed for a-mannosidase activity, b-galac-
tosidase activity (An et al. 1982), and protein concen-
tration (Bradford 1976).
Results
Identification of Mutations in the MANB Gene
On Southern blot analysis of EcoRI-digested genomic
DNA, with the full-length lysosomal a-mannosidase
cDNA (kindly provided by V. L. Nebes) used as a probe,
the DNA samples from the five patients showed patterns
identical to those from control subjects, indicating that
the patients had no large deletions of the gene (data not
shown). We next screened for mutations in the patients’
samples by using SSCP analysis, after all 24 exons and
flanking intron sequences were amplified by primers spe-
cific for the MANB gene (table 2). Mobilities that were
abnormal in comparison with those of control samples
were identified in exon 2 from patient 3 (cell line
GM2051), in exon 8 from patient 5 (cell line GM4518),
in exon 15 from patient 2 (cell line GM654), and in
exon 18 from both patient 2 (cell line GM654) and
patient 4 (cell line GM2817) (data not shown). On the
basis of direct sequence analyses of mutant PCR prod-
ucts from four patients’ samples, three homozygous
point mutations were identified in three patients: in pa-
tient 3, a His(H)-to-Leu(L) substitution at codon 72
(CATrCTT) (fig. 1A); in patient 5, a Pro(P)-to-Arg(R)
substitution at codon 356 (CCCrCGC) (fig. 1B); and,
in patient 4, an Arg(R)-to-Trp(W) substitution at codon
750 (CGGrTGG) (fig. 1D). Moreover, two heterozy-
gous mutations, a Gln(Q)-to-stop(X) substitution at co-
don 639 (CAGrTAG) (fig. 1C) and an Arg(R)-to-
Trp(W) substitution at codon 750 (CGGrTGG) were
identified in patient 2 (fig. 1D). No abnormal mobilities
were identified, by SSCP analysis, in the PCR products
from patient 1 (OK1). We therefore turned to direct
sequencing of all 25 PCR products in this patient, in a
search for probable mutations. Only one homozygous
point mutation, an Arg(R)-to-stop(X) substitution at co-
don 760 (CGArTGA), was identified (fig. 1E). The co-
don numbering used here is that of Wakamatsu et al.
(1997). The differences from the sequences of theMANB
gene reported by Nilssen et al. (1997) are due to an
additional three nucleotides—GCC, inserted after the
first ATGGGC nucleotide in the cDNA—which we also
identified in genomic DNA as well as in the cDNA. The
differences in the codon numbers of the mutations iden-
tified in our previous report (Gotoda et al. 1996) are
due to the differences in the sequences reported byNebes
and Schmidt (1994) and to numbering from the first
ATG (Wakamatsu et al. 1997). The identified mutations
are summarized in table 3.
Confirmation of Mutations, by PCR-Dependent
Restriction-Enzyme Diagnosis
To confirm the five mutations identified in patient leu-
kocytes and cell lines, we established diagnostic tests
specific to each mutation that were based on restriction-
enzyme cleavage of PCR products by primers flanking
the mutation site (table 2). The assays confirmed that
patients 1 and 3–5 appeared to be homozygous for their
identified mutations and that patient 2 was heterozygous
for the mutations Q639X and R750W (fig. 2). The sister
of patient 1 also was homozygous for the R760X mu-
tation (data not shown). Both alleles are confirmed as
R760X, since these patients’ parents are first cousins.
We used these same diagnostic testes to screen for each
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mutation in a set of 48 normal control subjects; and
none of the mutations was identified (data not shown),
confirming that these mutations do not represent fre-
quent polymorphisms.
a-Mannosidase Activity in COS 7 Cells
To establish whether themutationsH72L, P356R, and
R750W affect a-mannosidase activity, we introduced
each into the pCMV-Man vector, and the plasmids were
transiently expressed in COS 7 cells. Expression of the
pCMV-Man vector in COS 7 cells produced a-mannosi-
dase activity that was ∼20 times higher than that in
mock-transfected (i.e., transfected with pCMVb plasmid
only) COS 7 cells. However, a-mannosidase activity in
the mutant plasmids containing H72L, P356R, or
R750W showed no increase over background levels
(fig. 3).
Discussion
In the present study, we describe five mutations
(H72L, P356R, Q639X, R750W, and R760X) of the
human MANB gene in patients with a-mannosidosis.
Given the wide spectrum of clinical heterogeneity in pa-
tients with this disease, which in part could be due to
the presence of residual enzyme activity and altered ki-
netics of the enzyme, Desnick et al. (1976) hypothesized
that this disease most likely is caused by missense mu-
tations. To elucidate the specific molecular defects as-
sociated with the MANB gene, we examined mutations
in five patients with a-mannosidosis. Patient 1 (OK1)
and patient 2 (cell line GM654) have mild clinical phe-
notypes. Both patients showed psychomotor retardation
after the 1st year of life and developed recurring infec-
tions, hearing loss, impaired speech, and coarse facial
features. They survived to age 17 years (patient 2) and
age 147 years (patient 1). Two others, patient 3 (cell line
GM2051) and patient 4 (cell line GM2817), also most
likely have a mild form of a-mannosidosis, because they
have also survived to age x10 years. In contrast, patient
5 (cell line GM4518) showed severe growth failure with
hypotonia after birth and appeared to have a severe form
of the disease. Taken together, patients 1–4 probably
have type II a-mannosidosis, and patient 5 probably has
type I a-mannosidosis. The four distinct mutations iden-
tified in the patients confirm a probable genetic basis for
the heterogeneity in this disease (Gotoda et al. 1996),
although the nonsense mutations were unexpected in the
patients with type II a-mannosidosis.
Transfection studies using a-mannosidase cDNAs
containing the missense mutations H72L, P356R, or
R750W, which were identified in both types of patients,
did not show an increase in a-mannosidase activity in
COS 7 cells. This indicates that thesemutations are likely
to be at least three distinct genetic causes of a-mannosi-
dosis. The R750W mutation probably affects local
charge and secondary structure of the protein, with con-
sequent loss of enzymatic activity. In contrast, the H72L
mutation, which has been identified in the mild form of
the disease (Nilssen et al. 1997), is a conservative change
that does not affect the charge of the enzyme. This amino
acid, however, is probably critical to the function of the
enzyme, since it is conserved among the lysosomal a-
mannosidases of man, cattle, and Dictyostelium discoi-
deum, as well as among the class 2 a-mannosidases of
Drosophila and human Golgi and rat endoplasmic re-
ticulum (Nilssen et al. 1997). It is possible that the H-
to-L substitution affects the catalytic site or substrate-
recognition site on the enzyme.
The P356R mutation was identified in a severe form
of the disease. The affected residue, Pro356, and sur-
rounding amino acids are all conserved between a-man-
nosidase in man and that in D. discoideum (Schatzle et
al. 1992). Use of computer programs that calculate prob-
able secondary structure on the basis of amino acid se-
quences suggests that this region contains hydrophobic
amino acids predicted to form a b-sheet structure
(Schatzle et al. 1992). The positive charge on the argi-
nine—and subsequent disruption of the putative bend
resulting from this mutation—would dramatically
change the secondary structure of the enzyme.
a-Mannosidosis is a clinically heterogeneous disorder,
but enzyme-activity assays using a single concentration
of substrate do not easily account for the range in clinical
severity described in many patients (Noll et al. 1989).
Indeed, all five patients in the present study had a similar
deficiency of lysosomal a-mannosidase, at 2 mM 4-MU-
a-D-mannopyranoside (table 1). Recently, Bennet et al.
(1995) compared the biochemical analyses of a-man-
nosidase in patients with each clinical type of a-man-
nosidosis. Kinetic analysis showed that a-mannosidase
from type I patients had an ∼400-fold reduction in sub-
strate affinity, whereas those with type I had a substrate
affinity reduced by only 40-fold. Bennet et al. concluded
that the markedly decreased substrate affinity of the en-
zyme correlated with the severity in phenotypic expres-
sion. In this context, the P356R mutation would be ex-
pected to strongly change the secondary structure of the
enzyme, thereby markedly reducing its affinity for the
substrate and resulting in a severe form of the disease.
In contrast, the R750W mutation would more likely
have less of an effect on substrate affinity, resulting in
a milder form of the disease. However, the fact that both
types of patients have been documented as being in the
same family (Spranger et al. 1976; Mitchell et al. 1981)
suggests that the phenotype may be influenced by factors
other than just the primary gene defect; environmental
agents or unidentified modifier genes may contribute to
the heterogeneous clinical presentation. Nevertheless, a
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more extensive accumulation of different mutations
from patients with mild to severe forms of the disease
should help in the elucidation of any genotypic/pheno-
typic relationships.
The homozygous nonsense mutation, R760X, was
identified in exon 19 from a patient with a milder form
of a-mannosidosis. This is in stark contrast with what
is seen in other lysosomal-storage diseases, such as Tay-
Sachs disease and Sandhoff disease, where homozygous
nonsense mutations are observed mostly in patients with
the severe, infantile form of the disease (Gravel et al.
1995). The nonsense mutation in the a-mannosidase
gene is located in exon 19, at a point ∼75% along the
length of the protein. This nonsense mutation likely en-
codes an unstable mRNA, such that a relatively stable
but defective protein is produced that can show partial
activity toward a-mannose residues in vivo. It also sug-
gests that the C-terminus may be of limited importance
for enzyme synthesis or lysosomal targeting. In the effort
to further clarify the functional relevance of the C-ter-
minus of a-mannosidase, the R760X mutation or a sim-
ilar deletion near the C-terminus may provide important
clues relative to the activity of the defective enzyme and
its kinetics.
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